Abstract:Science Progress, Volume 107, Issue 4, October-December 2024. ObjectiveThe pathological mechanism of osteoporosis (OP) involves increased bone resorption mediated by osteoclasts and decreased bone formation mediated by osteoblasts, leading to an imbalance in bone homeostasis. Identifying key molecules in osteoclast-mediated OP progression is crucial for the prevention and treatment of OP.MethodsDifferential expression analysis and weighted gene co-expression network analysis (WGCNA) were performed on the OP patient datasets from the GEO database. The results were intersected with the differential expression results from the osteoclast differentiation dataset to identify key genes. These key genes were then subjected to disease relevance analysis, and consensus clustering was performed on OP patient samples based on their expression profiles. The subgroups were analyzed for differences, followed by GO, KEGG, GSEA, and GSVA analyses, and immune infiltration. Finally, osteoclast differentiation model was constructed. After validating the success of the model using TRAP and F-actin staining, the differential expression of key genes was validated in vitro via Western blot.ResultsCTRL, ARHGEF5, PPAP2C, VSIG2, and PBLD were identified as key genes. These genes exhibited strong disease relevance (AUC > 0.9). Functional enrichment results also indicated their close association with OP and osteoclast differentiation. In vitro differential expression validation showed that during osteoclast differentiation, CTRL was downregulated, while ARHGEF5, PPAP2C, VSIG2, and PBLD were upregulated, with all differences being statistically significant (P < 0.05).DiscussionCurrently, there are no studies on the effects of these five genes on osteoclast differentiation. Therefore, it is meaningful to design in vivo and in vitro perturbation experiments to observe the impact of each gene on osteoclast differentiation and OP progression.ConclusionCTRL, ARHGEF5, PPAP2C, VSIG2, and PBLD show high potential as molecular targets for basic and clinical research in osteoclast-mediated OP.

Cytoplasmic PCNA is located in the actin belt and involved in osteoclast differentiation

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

Cytoplasmic Hnrnpk Interacts with GSK3β and is Essential for the Osteoclast Differentiation

Osteoclast Differentiation and Gene Regulation

Cortactin controls bone homeostasis through regulating the differentiation of osteoblasts and osteoclasts

P2X7 receptor knockdown suppresses osteoclast differentiation by inhibiting autophagy and Ca2+/calcineurin signaling

The molecular understanding of osteoclast differentiation

The role of calcium release activated calcium channels in osteoclast differentiation

LncRNA AK077216 promotes RANKL‐induced osteoclastogenesis and bone resorption via NFATc1 by inhibition of NIP45

Involvement of Noncoding RNAs in the Differentiation of Osteoclasts

Atp6v1c1 is an Essential Component of the Osteoclast Proton Pump and in F-Actin Ring Formation in Osteoclasts

Inhibitory Effects of N-[2-(4-acetyl-1-piperazinyl) Phenyl]-2-(2-chlorophenoxy) Acetamide on Osteoclast Differentiation in Vitro Via the Downregulation of TRAF6

Annexin A3 Accelerates Osteoclast Differentiation by Promoting the Level of RANK and TRAF6

CircFam190a: a Critical Positive Regulator of Osteoclast Differentiation Via Enhancement of the AKT1/HSP90β Complex.

PGC1β Organizes the Osteoclast Cytoskeleton by Mitochondrial Biogenesis and Activation

Mechanical Protein Polycystin-1 Directly Regulates Osteoclastogenesis and Bone Resorption

Integrin-associated Molecules and Signalling Cross Talking in Osteoclast Cytoskeleton Regulation.

Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1‐targeting miRNA‐92a‐1‐5p

Identification and functional analysis of genes mediating osteoclast-driven progression of osteoporosis

Poria Cocos Polysaccharide Attenuates RANKL-induced Osteoclastogenesis by Suppressing NFATc1 Activity and Phosphorylation of ERK and STAT3.

[Osteoclast Differentiation Regulated by Receptor Activator of Nuclear Factor Kappab Probably Through a Novel Signaling Pathway].